Cubist Systematic Strategies, LLC Rubius Therapeutics, Inc. Transaction History

Cubist Systematic Strategies, LLC

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	SELL	$0.46 - $1.29 $28,881 - $80,992	-62,785 Reduced 77.46%	18,270 $8,000
Q2 2022 Aug 15, 2022	SELL	$0.79 - $5.98 $60,617 - $458,851	-76,731 Reduced 48.63%	81,055 $69,000
Q1 2022 May 16, 2022	BUY	$4.25 - $10.4 $537,501 - $1.32 Million	126,471 Added 403.87%	157,786 $869,000
Q4 2021 Feb 14, 2022	BUY	$9.68 - $17.74 $220,026 - $403,230	22,730 Added 264.76%	31,315 $303,000
Q3 2021 Nov 15, 2021	SELL	$17.6 - $25.91 $92,523 - $136,208	-5,257 Reduced 37.98%	8,585 $153,000
Q2 2021 Aug 16, 2021	BUY	$22.26 - $28.43 $135,652 - $173,252	6,094 Added 78.65%	13,842 $338,000
Q1 2021 May 17, 2021	BUY	$8.02 - $32.01 $62,138 - $248,013	7,748 New	7,748 $205,000
Q1 2020 May 15, 2020	SELL	$3.74 - $9.84 $66,530 - $175,043	-17,789 Closed	0 $0
Q4 2019 Feb 14, 2020	BUY	$7.23 - $14.12 $29,144 - $56,917	4,031 Added 29.3%	17,789 $169,000
Q3 2019 Nov 14, 2019	BUY	$7.85 - $15.75 $108,000 - $216,688	13,758 New	13,758 $108,000

325

Ticker RUBY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 90,357,000
Description
Rubius Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of red cell therapeutics (RCTs) for the treatment of patients with severe diseases. The company is developing RTX-240 and RTX-224 for the treatment of solid tumors cancer; and RTX-aAPC to treat cancers. It is also developing RTX-321 for the treatmen...

Get notified when there are updates to the investment portfolio of Cubist Systematic Strategies, LLC, based on Form 13F filings with the SEC.

Stay updated on Cubist Systematic Strategies, LLC with notifications on news.